Life science incubator BioCity has invested in a firm whose innovation will be used to improve monitoring of the response and results of drugs used in cancer treatment.
Kinomica is a spin out from Barts Cancer Institute, Queen Mary University of London, and has created technologies which can assist therapeutic development in precision medicines, a key priority for the Government.
The investment from BioCity , headquartered in Nottingham , has been made through the Innovate UK Precision Medicine Investment Accelerator.
Claire Brown, director of investment, said: "We believe Kinomica are at the forefront of a new area.
"While genomic approaches have been successful in allowing the stratifying of patients, increasingly, understanding the molecular ‘re-wiring’ of tumours, such as that provided by KinoScan, is critical.
"Kinomica provides unique insights that Pharma will be able to leverage, as evidenced by the traction already made to date with key partners in this sector."
Kinomica is based at Alderley Park, Cheshire, where BioCity recently expanded its presence.
The firm's flagship KinoScan innovation, while focusing on oncology, could also be used in other areas such as autoimmune diseases, rheumatoid arthritis and neurological diseases.
Jane Theaker, the company's CEO said: "We are really excited that our Pharma customers and investors see the value of cell-signal profiling to gain insights that have a huge positive impact on patients lives."
